Abstract: Aromatase inhibitors (AI) induce painful musculoskeletal symptoms (AIMSS), which are dependent upon the pain transducing receptor TRPA1. However, since the AI concentrations required to engage TRPA1 in mice are higher than those found in the plasma of patients, we hypothesized that additional factors may cooperate to induce AIMSS. Here we report that the aromatase substrate androstenedione, unique among several steroid hormones, 
Introduction
Aromatase inhibitors (AIs) are a mainstay in the treatment of estrogen-sensitive breast cancer in postmenopausal women (1) . AIs block the activity of aromatase cytochrome P450, which transforms the androgens, androstenedione and testosterone into the estrogens (estrone and 17β-estradiol, respectively) (2), which are responsible for cancer cell replication and growth (3) . Unfortunately, one-third of patients treated with AIs develop muscular and joint pain (aromatase inhibitor-associated musculoskeletal symptoms, AIMSS), a condition that affects the quality of life of patients and limits adherence to AI therapy (4, 5, 6) . The underlying mechanism of AIMSS is unknown and, accordingly, the treatment of AIMSS remains an unmet medical need.
Recently, we reported that the transient receptor potential ankyrin 1 (TRPA1), a cation channel highly expressed by a subpopulation of primary sensory neurons of the dorsal root ganglia (DRG) (7), mediates AIMSS-like behaviors evoked by AIs in mice (8) . TRPA1-expressing nociceptors contain the neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP), which mediate neurogenic inflammation (9). Exogenous compounds, including allyl isothiocyanate (AITC), and endogenously generated reactive oxygen species (ROS) and their derivatives, have been identified as TRPA1 agonists (9-12). Similar to other reactive agonists (7) , highly electrophilic conjugated Michael acceptor groups of exemestane (13) and nitrile moieties of letrozole and anastrozole (14) react with the thiol groups of specific cysteine and lysine residues to trigger TRPA1 and activate nociceptors (8) .
The ability to gate TRPA1 in vitro was confirmed in vivo by the observation that the painlike behaviors evoked by AIs in mice are abrogated by genetic deletion or pharmacological blockade of the channel (8) . However, AI concentrations required for TRPA1 gating in vitro (8) are 1-2 order of magnitude higher than those found in patient plasma (15) . In addition, an important proportion (30-40%), but not all, of treated patients develop the painful condition 5 (16, 17) . These observations suggest that exposure to AIs is necessary, but not sufficient, to produce AIMSS, and that additional factors should cooperate with AIs to promote pain symptoms.
Aromatase inhibition, while reducing downstream production of estrogens, moderately increases upstream plasma concentrations of androgens, including androstenedione (ASD) (18) .
Exemestane, a false aromatase substrate, blocks enzymatic activity by accommodating in the binding pocket that snugly encloses ASD (2) . We reasoned that ASD, which retains some of the reactive chemical features of exemestane, such as the α,β-carbonyl moiety of the A ring and the ketone group at the 17 position, might target TRPA1 ( Supplementary Fig. S1A ). In this paper, we report that ASD, unique among several steroid hormones upstream to aromatase, targets the recombinant and native TRPA1, thereby, alone or in combination with oxidative stress byproducts, contributing to dramatically lowering the concentrations/doses of letrozole required to engage TRPA1 in vitro and produce TRPA1-dependent AIMSS-like behaviors in mice.
Material and Methods

Animals
In vivo experiments and tissue collection were carried out according to the European mice, and cultured as previously described (8) .
Cellular Recordings
Intracellular calcium was measured as previously reported (8) . Results are expressed as the percentage of increase of Ratio340/380 over the baseline normalized to the maximum effect induced by ionomycin (5 µM) (% Change in R340/380) or as the percentage of responding neurons, identified by KCl (50 mM). Whole-cell patch-clamp recordings were performed as reported elsewhere (8) . Peak currents were normalized to cell membrane capacitance and expressed as mean of the current density (pA/pF) in averaged results. Currents were evoked in the voltage-clamp mode at a holding potential of -60 mV; signals were sampled at 1 kHz and low-pass filtered at 10 kHz. Capsaicin (0.1 or 1 µM) has been used to identify TRPV1-expressing nociceptors. for 60 seconds, centrifuged at 12,000xg for 20 minutes at 4°C, and the supernatant was used to determine the H2O2 content. H2O2 levels were detected by using the phenol red-HRPO method (27, 28) corrected by protein content and expressed as µmol/mg of proteins (29) .
Behavioral experiments
Immunostaining
C57BL/6 mice were anesthetized with a mixture (i.p.) of ketamine (90 mg/kg) and xylazine (3 mg/kg), and transcardially perfused with phosphate buffer saline followed by 4%
paraformaldehyde. The sciatic nerve with the surrounding tissue was removed and embedded in paraffin. Immunofluorescence staining for 4-hydroxynonenal adducts and TRPA1 was performed as previously reported (30) .
Plasma protein extravasation
BSO was given 30 minutes before letrozole, and ASD immediately after letrozole; mice were anesthetized 15 minutes after letrozole as previously described (10). HC-030031 (100 mg/kg, i.p.) or its vehicle (4% DMSO plus 4% Tween80, i.p.), or a combination of L-733,060
and CGRP8-37, (NK1/CGRP-RA; both 2 μmol/kg, i.v.) or its vehicle (isotonic saline), were administered 60 minutes or 15 minutes before ASD, respectively. The extravasated dye was extracted from synovial tissue of the knee joint by overnight incubation in formamide, and assayed by spectrophotometry at 620 nm, as previously reported (20) .
Synovial fluid lavage
The synovial fluid was collected from anesthetized mice treated with the combination of BSO (i.p.), letrozole (i.g.) and ASD (i.p.), or their vehicles (isotonic saline, 0.5% CMC and 4%
DMSO plus 4% Tween80, respectively). BSO was given 30 minutes before letrozole and ASD immediately after letrozole. Synovial fluid was collected by instilling 3 times 0.1 ml of Hank's Buffer plus 10 mM HEPES and 10 mM EDTA in the knee 15 minutes after letrozole. The neutrophil count was performed using standard morphological criteria on Diff-Quick stained cytospins. Data are expressed as total number of neutrophils in 100 µl of solution.
CGRP-Like Immunoreactivity assay
Slices (0.4 mm) of rat spinal cords were superfused with ASD or vehicle. Tissues were pre-exposed to capsaicin (10 µM, 20 minutes), superfused with a calcium-free buffer containing EDTA (1 mM), and pretreated with HC-030031 (50 µM) or capsazepine (10 µM).
Superfusate fractions (4 ml) were collected at 10-minute intervals before, during, and after stimulus administration, freeze-dried, reconstituted with assay buffer, and analyzed for CGRPlike immunoreactivity (LI) as previously described (8 
Data Analysis
Data represent mean±SEM. Statistical analysis was performed by the unpaired two-tailed Student's t-test for comparisons between two groups, and the ANOVA, followed by the Bonferroni post-hoc test, for comparisons between multiple groups (GraphPadPrism version 5.00, San Diego, CA, USA). Agonist potency was expressed as half maximal effective concentration (EC50); that is, the molar concentration of an agonist producing 50% of the maximum measured effect. P<0.05 was considered statistically significant.
Results
ASD selectively activates the recombinant and native human TRPA1 by targeting key electrophilic amino acid residues
In hTRPA1-HEK293 cells, but not in untransfected HEK293 cells, ASD evoked calcium responses in a concentration-dependent manner (EC50, 49 µM) ( Fig. 1A and Supplementary Fig. S1B ). Responses to both ASD and the TRPA1 agonist, AITC, were abrogated by HC-030031 (Fig. 1B) . Consistently, hTRPA1-HEK293 cells superfused with ASD elicited concentration-dependent inward currents ( Supplementary Fig. S1E ), an effect blocked by HC-030031 (Fig. 1C ) and absent in untransfected HEK293 cells (Fig. 1D) . In hTRPV1-HEK293 and hTRPV4-HEK293, activated by the selective TRPV1 agonist, capsaicin, or the selective TRPV4 agonist, GSK1016790A, respectively, ASD failed to evoke calcium responses or inward currents ( Fig. 1E and 1F) . Notably, hTRPA13C/K-Q-HEK293
did not respond to AITC or ASD, while they did respond to the non-electrophilic TRPA1 agonist, menthol ( Fig. 1G and Supplementary Fig. S1D ) (8) .
In IMR90 cells, which constitutively express the TRPA1 channel (31) and do not respond to capsaicin, indicating the absence of a functional TRPV1 channel (Fig. 1H) , ASD produced concentration-dependent (EC50, 37 µM) calcium responses that were fully and selectively inhibited by HC-030031 ( Fig. 1H and Supplementary Fig. S1C ). Similar results were obtained in electrophysiology experiments, where ASD activated TRPA1-mediated inward currents that were entirely and selectively abolished by HC-030031 ( Fig. S1E ).
ASD excites DRG neurons by a prominent role of TRPA1 and, surprisingly, with the contribution of TRPV1
ASD evoked concentration-dependent (EC50 = 27 µM) calcium responses in a subset of rat DRG neurons, identified by their ability to respond to KCl, AITC and capsaicin as nociceptors (23) ( Fig. 2A and Supplementary Fig. S1F ). Capsaicin-sensitive neurons that did not respond to AITC were also unresponsive to ASD (Fig. 2A) . The percentages of ASD-14 responding and AITC-responding neurons out of the KCl-responding neurons were similar (Fig. 2B) . Superimposable findings were obtained by electrophysiological recording (Fig. 3A) .
Surprisingly, the remarkable ASD selectivity for TRPA1 was challenged by experiments in rat DRG neurons. The selective TRPV1 antagonist, capsazepine, reduced both the calcium response and the inward currents evoked by ASD, and it abated the residual response observed in the presence of HC-030031 (Fig. 2C and 2D and Fig. 3A) . The calcium response to ASD was, however, unaffected by the selective TRPV4 antagonist, HC-067047 (Fig. 2D) . Results obtained in rat DRG neurons were replicated in mouse DRG neurons. Cells obtained from
Trpa1
-/-mice exhibited a residual calcium response to ASD that, being consistently unaffected by HC-030031, was abated by capsazepine (Fig. 2E) . The percentages of ASD-responding and AITC-responding neurons out of the KCl-responding neurons were similar ( (Fig. 2F) .
To confirm the contribution of TRPV1 in the overall response to ASD, we used hTRPA1/V1-HEK293 cells (22) , where the calcium response evoked by ASD was reduced by both HC-030031 and capsazepine, and was abated solely by the combination of the two antagonists, while responses to AITC and capsaicin were fully attenuated by respective antagonists (Fig. 2G) . Thus, TRPV1, when co-expressed with TRPA1, as constitutively happens in DRG neurons, appears to contribute to the response to ASD.
CGRP release from slices of the rat dorsal spinal cord, an anatomical site enriched with terminals of TRPA1-positive peptidergic nociceptors, illustrates the ability of ASD to activate such neurons (8) . The increased CGRP-LI outflow by ASD was abated by the removal of extracellular calcium, previous desensitization to capsaicin, or in the presence of HC-030031, 15 but only partially reduced by capsazepine (Fig. 2H) . Thus, ASD elicits CGRP release from a subset of TRPV1-positive neurons via a neurosecretory process, mediated by TRPA1.
ASD cooperates with letrozole and H 2 O 2 to excite nociceptors in vitro
To explore whether ASD cooperates with AIs and proinflammatory mediators to excite nociceptors via a TRPA1-dependent final common pathway, we used letrozole, the most prescribed AI in clinical practice (32) . As a prototypical proinflammatory mediator, we selected the ROS H2O2, because oxidative stress is increased by breast cancer (33) and letrozole (34) . In addition, the effect of letrozole (0.5 mg/kg, i.g.), at a dose that was previously shown to produce per se mechanical allodynia, was partially reduced by the antioxidant, α-lipoic acid ( Supplementary Fig. S2 ). These observations suggest that the TRPA1-dependent letrozoleevoked mechanical hypersensitivity (8) is partially due to ROS generation, which cooperates with the anticancer drug to target TRPA1.
From the concentration-response curves of ASD, letrozole, and H2O2 ( Fig. 3A-C) , we selected subthreshold concentrations that were unable to elicit measurable inward currents in rat DRG neurons, and combined a per se inactive concentration of ASD with inactive concentrations of letrozole or H2O2 (ASD/letrozole or ASD/H2O2). Interestingly, we found that each combination evoked inward currents, which were abated by TRPA1 antagonism and reduced by TRPV1 antagonism (Fig. 3D) . Finally, we identified an inactive combination of letrozole and H2O2 (Fig. 3E) , and we found that adding an inactive ASD concentration to it triggered an inward current that was abated by HC-030031 and only partially reduced by capsazepine (Fig. 3E ).
ASD cooperates with letrozole and H 2 O 2 to produce local TRPA1-dependent mechanical allodynia
Previous in vitro findings were translated to an in vivo setting. Injection of ASD (1-10 nmol/paw) into the mouse paw did not evoke any acute nociceptive behavior (data not shown).
However, 30 minutes after the injection, and for the following 2 hours, ASD produced a dosedependent mechanical allodynia ( Fig. 4A and 4B ) that was partially and completely abrogated by capsazepine and HC-030031, respectively (Fig. 4B ). H2O2 injected in the mouse paw produced a dose-dependent mechanical allodynia that was entirely dependent on TRPA1 (Fig.   4C ). Similar to previous findings (8), systemic letrozole (0.1-0.5 mg/kg, i.g.) evoked a dosedependent, delayed (1-6 hours) mechanical allodynia that was abated by HC-030031 and unaffected by capsazepine (Fig. 4D) . The combined administration of allodynia-evoking doses of ASD and letrozole produced an exaggerated pain-like response ( Supplementary Fig. S3A ).
Next, we found doses of ASD and letrozole, or H2O2 and ASD, which, although per se ineffective, when given in combination, lowered the threshold for eliciting mechanical allodynia ( Supplementary Fig. S3B and S3C ). Finally, we identified ineffective combinations of ASD/letrozole, letrozole/H2O2, or H2O2/ASD that, when given simultaneously (letrozole/ASD/H2O2), caused mechanical allodynia (Fig. 4E ). This response was partially reduced by capsazepine, completely reverted by HC-030031 (Fig. 4F) , and absent in Trpa1 -/- (Fig. 4G ).
ASD cooperates with letrozole and H 2 O 2 to produce systemic TRPA1-dependent AIMSS-like behaviors and neurogenic inflammation
In mice, letrozole (0.5 mg/kg, i.g.) has been reported to evoke TRPA1-dependent mechanical allodynia and a decrease in grip strength, two effects reminiscent of AIMSS (8) .
The same dose of letrozole (0.5 mg/kg, i.g.) (8) increased H2O2 in the sciatic nerve tissue and slightly augmented ASD serum levels ( Fig. 5A and 5C ). BSO, by inhibiting γ-glutamylcysteine synthetase, causes systemic depletion of glutathione, and the ensuing increase in ROS (35) .
BSO (800 mg/kg, i.p.) increased mechanical allodynia and decreased forelimb grip strength through a TRPA1-dependent mechanism ( Supplementary Fig. S4A) , while, at the dose of 400 mg/kg, it slightly increased H2O2 in the sciatic nerve tissue (Fig. 5C ) without affecting painlike behaviors (Supplementary Fig. S4A ). Finally, systemic administration of ASD (2 μg/kg, i.p.) caused, in mice, mechanical allodynia and reduced forelimb grip strength via TRPA1, with a partial contribution of TRPV1 ( Supplementary Fig. S4B ). ASD (2 μg/kg, i.p.) also increased H2O2 levels in the sciatic nerve (Fig. 5C ).
To better understand the contribution of ASD and oxidative stress to the AIMSS-like behaviors, a low dose of ASD (0.2 μg/kg, i.p.) that failed to affect H2O2 generation (Fig. 5C ), as well as mechanical allodynia and forelimb grip strength, (Supplementary Fig. S4B ) was used. This same dose slightly increased hormone plasma concentration to levels comparable to those produced by a dose of letrozole (0.5 mg/kg, i.g.) that caused pain-like behaviors ( Fig. 5A and Fig. 4D ). In mice, 1 hour after oral administration of letrozole (0.1 and 0.5 mg/kg), drug concentrations in plasma were 13.5 ± 2.0 ng/ml (n = 4) and 55.3 ± 4.8 ng/ml (n = 4), respectively, whereas 3 hours after dosing, plasma concentrations were 8.41 ± 1.0 ng/ml (n = 4) and 45.4 ± 6.11 ng/ml (n = 4), respectively. Notably, the plasma concentration of 0.5 mg/kg letrozole measured at 1 hour after dosing was similar to that found previously (8) . Systemic BSO (400 mg/kg, i.p.), letrozole (0.1 mg/kg, i.g.) and ASD (0.2 g/kg, i.p.), which per se, or in combinations (letrozole/ASD, BSO/ASD or BSO/letrozole), did not affect behavioral responses, when given simultaneously caused remarkable mechanical allodynia and decreased forelimb grip strength ( Fig. 5D and 5E ). The triple combination of BSO, letrozole, and ASD increased H2O2 levels in the sciatic nerve (Fig. 5C) . However, the increase equals that evoked by BSO (400 mg/kg) alone. Finally, the remarkable increase in 4-hydroxynonenal staining in the sciatic nerve allowed us to localize the oxidative stress generation within the neural structure (Fig. 5H ). Behavioral responses evoked by the triple combination were partially and totally reverted by capsazepine and HC-030031, respectively ( Fig. 5D and 5E ), and were absent in Trpa1 -/-mice, but unaffected in Trpv1 -/-mice ( Fig. 5F and 5G) .
Finally, the combination of BSO (400 mg/kg, i.p.), letrozole (0.1 mg/kg, i.g.) and ASD (0.2 g/kg, i.p.), which produced AIMSS-like behaviors, increased Evans blue dye extravasation in the synovial tissue and the number of neutrophils in the synovial fluid of mouse knee joint ( Fig. 5I and 5J ). Both responses were reduced by pretreatment with HC-030031 or a combination of L733,060 and CGRP8-37 (both 2 µmol/kg, i.v.) ( Fig. 5I and 5J ). These findings indicate that the letrozole/ASD/BSO combination via TRPA1 promotes two typical neurogenic inflammatory responses, such as plasma protein and neutrophil extravasation (9).
Discussion
We found that ASD, unique among several steroid hormones, activates TRPA1, thereby promoting AIMSS-like responses. ASD behaves as a TRPA1 agonist across species, as it engages both the recombinant and native human channel and the rat and mouse channel. TRPA1 activation by ASD, similar to other electrophilic agonists (7), requires the presence of three cysteine (C619, C639, C663) and one lysine (K708) key residues. Furthermore, ASD exhibits a peculiar selectivity profile. Whereas in cells expressing only one channel (transfected HEK293 cells, IMR90 human fibroblasts) (31, 36) , ASD is a selective TRPA1 agonist, surprisingly, in rodent DRG neurons, which express multiple TRP channels, TRPV1
contributes to TRPA1-dependent ASD-evoked responses. Notably, DRG neurons from Trpa1 with remarkable selectivity, they exhibit low potency at both human and rodent channels (8) .
Notably, the peak plasma concentration of letrozole measured in mice in the present study after the 0.5 mg/kg dose (~194 nM) is close to the maximum concentration reported in human plasma after a single therapeutic dose (2.5 mg) (~128 nM) (45) . It must be underlined that the plasma concentrations found in mice and humans are 50-400 times lower than the threshold concentrations of letrozole able to gate in vitro the mouse, rat or human TRPA1 (>10 μM ANOVA and Bonferroni post hoc test.
